Totally agree, shareholders quoting Dr T, Leslie, Fong, or anyone else’s resume or actions as a sign of a good investment is in-experienced.
I often see it referenced in both companies, “Surely they wouldn’t spend millions if XYZ wasn’t confident”:
Yes they would. 90%+ biotech’s fail to bring a drug to market for various reasons, efficacy, trial design, execution, timing, competitive landscape, pricing, insurers/payers, market size or ability to scale, the list goes on.
All we can do at this stage is question the science and R&D in what is announced or publicly available. Something shareholders aren’t doing enough of by trusting managements comments and not looking at the data closely in its entirety.
The CF33, Vaxinia and Oncarlytics Deal, page-364
-
- There are more pages in this discussion • 724 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |